Molecular Insights into the Potential Cardiometabolic Effects of GLP-1 Receptor Analogs and DPP-4 Inhibitors. [PDF]
Król M +6 more
europepmc +1 more source
In 1,468 patients with type 2 diabetes, central obesity (WHtR >0.5) neutralizes the protective effects of higher BMI on muscle strength. Concurrently, visceral adiposity and CKD impose an additive threat, maximizing low handgrip strength risk (aOR = 1.74). Combining WHtR and renal tracking optimizes clinical sarcopenia screening.
Shing‐Hua Chen +4 more
wiley +1 more source
GLP-1 Receptor Agonists, DPP-4 Inhibitors and the Skin-Diabetes Meets Dermatology: A Brief Narrative Review. [PDF]
Pantazopoulos D +4 more
europepmc +1 more source
Among participants aged 40–75 years, sarcopenic obesity was observed in 4.9% of those with T2D and 0.5% of non‐D individuals. Sarcopenic obesity is more prevalent in individuals with T2D and is associated with impaired physical QOL, reduced walking ability, and increased falls.
Hiroyasu Mori +12 more
wiley +1 more source
Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: a systematic review and meta-analysis. [PDF]
Hajishah H +9 more
europepmc +1 more source
Do Intoxicated Offenders Deserve Harsher Sentences? Questioning Veritas in Vino
ABSTRACT Criminal courts increasingly treat intoxication as an aggravating rather than a mitigating factor in sentencing. This shift, seen in Australian law and other jurisdictions, raises the prospect of unjust outcomes. We examine this trend through the lens of desert‐based justifications for punishment, setting aside questions of deterrence and ...
Mary Jean Walker, Daniel B. Cohen
wiley +1 more source
Retraction: Cardiovascular and mortality outcomes of DPP-4 inhibitors vs. sulfonylureas as metformin add-on therapy in patients with type 2 diabetes: A systematic review and meta-analysis. [PDF]
PLOS One Editors.
europepmc +1 more source
Association of Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review
ABSTRACT Introduction Increased risk of suicidality has been reported in association with glucagon‐like peptide receptor agonist (GLP‐1 RA) prescription. Herein, we conducted a comprehensive review evaluating reports of GLP‐1 RA prescription and suicidality.
Hezekiah C. T. Au +9 more
wiley +1 more source
GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani +8 more
wiley +1 more source

